Back
Science

Genetic Mutation Discovered to Impede Schizophrenia Drug Effectiveness

View source

Genetic Key to Schizophrenia Treatment Response Unlocked

Researchers in Australia have identified a rare genetic mutation that may explain why certain individuals do not respond to newer schizophrenia treatments. A study published in Genomic Psychiatry by Flinders University indicates that an inherited genetic change in the brain can completely block the function of the trace amine-associated receptor 1 (TAAR1). This receptor is a target for newer schizophrenia medications, rendering these drugs ineffective for individuals with the mutation.

"An inherited genetic change in the brain can completely block the function of the trace amine-associated receptor 1 (TAAR1), a target for newer schizophrenia medications."

Mutation Details

Pramod Nair, a senior research fellow at Flinders University and the study's principal investigator, stated that while TAAR1-based therapies are an emerging alternative for schizophrenia treatment, individuals possessing this mutation are unlikely to benefit.

The research specifically investigated a rare TAAR1 genetic variant, C182F. This mutation prevents the receptor from functioning by causing it to misfold, thereby blocking the binding site for drugs and natural molecules.

Nair explained that the mutation causes the receptor to become entirely non-responsive, effectively locking it shut and preventing even new drugs from activating it.

The research team noted the completeness with which the mutation disabled the receptor.

Implications for Treatment

The C182F mutation is rare globally but is observed more frequently among South Asian populations. Nair emphasized the importance of genetic screening prior to initiating schizophrenia treatment.

These findings contribute new insights into the causes of schizophrenia and underscore the necessity of personalized medicine, which involves tailoring treatments based on an individual's genetic profile. Approximately 23 million people globally are affected by schizophrenia. Existing medications primarily target dopamine, but they are not universally effective and can result in significant side effects.